Lyme Disease Diagnostic Market Forecast: Advanced Molecular Testing and Early Detection Innovations
The Lyme Disease Diagnostic Market is evolving as healthcare systems focus on early and accurate detection of tick-borne infections.
Lyme disease, caused by Borrelia burgdorferi, has become a significant public health issue in North America and Europe. Diagnostic advancements—including ELISA, Western blot, and polymerase chain reaction (PCR) tests—have improved clinical sensitivity and specificity. Growing public awareness, along with increased incidence in endemic regions, has prompted governments to implement national screening guidelines and surveillance programs. The integration of molecular diagnostics and next-generation sequencing (NGS) is enhancing the precision of early detection.
The Lyme Disease Diagnostic Market forecast suggests steady growth due to the rising adoption of point-of-care testing and AI-driven image recognition for skin lesions. Key challenges include misdiagnosis, lack of standardized testing procedures, and varying awareness among clinicians. However, collaborations between biotech firms and research institutes are leading to novel biomarker discovery and multiplex assays that detect co-infections. With continued…